Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy

  • OKA Satoko
    Division of Hematology, Japanese Red Cross Society Wakayama Medical Center
  • TAKEUCHI Suguru
    Division of Hematology, Japanese Red Cross Society Wakayama Medical Center
  • SHIRAGAMI Hiroshi
    Division of Hematology, Japanese Red Cross Society Wakayama Medical Center
  • HAMAHATA Keigo
    Division of Hematology, Japanese Red Cross Society Wakayama Medical Center
  • NOHGAWA Masaharu
    Division of Hematology, Japanese Red Cross Society Wakayama Medical Center

Bibliographic Information

Other Title
  • Lenalidomide投与中の静脈血栓塞栓症にapixabanが奏効した多発性骨髄腫
  • 症例報告 第4回日本血液学会関東甲信越地方会 奨励賞 Lenalidomide投与中の静脈血栓塞栓症にapixabanが奏効した多発性骨髄腫
  • ショウレイ ホウコク ダイ4カイ ニホン ケツエキ ガッカイ カントウ コウシンエツチホウカイ ショウレイショウ Lenalidomide トウヨ チュウ ノ ジョウミャク ケッセン ソクセンショウ ニ apixaban ガ ソウコウ シタ タハツセイ コツズイシュ

Search this article

Abstract

<p>A 69-year-old man was diagnosed with multiple myeloma (IgG-κ) in January 2012. He received autologous hematopoietic stem cell transplantation in August 2012 and subsequently maintained a stringent complete remission. In March 2016, he relapsed and was treated with lenalidomide and low-dose dexamethasone (Ld). On day22, he developed an asymptomatic venous thromboembolism (VTE) despite receiving prophylactic aspirin treatment. Thus, heparin and warfarin were administered. However, his prothrombin time-international normalized ratio did not remain within the target range of 2-3. Therefore, 10 mg/day of apixaban, a factor Xa inhibitor, was administered. The apixaban treatment resulted in favorable and effective control of the patient’s VTE on day33. He has continued to receive Ld treatment and has suffered no further VTE or bleeding. Further large studies are needed to assess the efficacy and safety of factor Xa inhibitors for the treatment of MM-associated VTE.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 58 (1), 37-41, 2017

    The Japanese Society of Hematology

Details 詳細情報について

Report a problem

Back to top